These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
141 related items for PubMed ID: 23798725
1. Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine. Depré M, Macleod C, Palcza J, Behm M, de Lepeleire I, Han T, Panebianco D, Smith W, Blanchard R, Chodakewitz J, Murphy M, de Hoon J. Cephalalgia; 2013 Dec; 33(16):1292-301. PubMed ID: 23798725 [Abstract] [Full Text] [Related]
2. Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. Hewitt DJ, Martin V, Lipton RB, Brandes J, Ceesay P, Gottwald R, Schaefer E, Lines C, Ho TW. Headache; 2011 Apr; 51(4):533-43. PubMed ID: 21457238 [Abstract] [Full Text] [Related]
3. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, Michelson D. Neurology; 2014 Sep 09; 83(11):958-66. PubMed ID: 25107879 [Abstract] [Full Text] [Related]
4. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, Fan X, Aurora SK, Brandes JL, Fei K, Beebe L, Lines C, Krucoff MW. Headache; 2012 Feb 09; 52(2):224-35. PubMed ID: 22221076 [Abstract] [Full Text] [Related]
5. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK. Lancet; 2008 Dec 20; 372(9656):2115-23. PubMed ID: 19036425 [Abstract] [Full Text] [Related]
6. Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study. Behm MO, Blanchard RL, Murphy MG, Palcza JS, Harris DE, Butterfield KL, Smith WB, Preston RA, Chodakewitz JA, Krucoff MW. Headache; 2011 Jun 20; 51(6):954-60. PubMed ID: 21631478 [Abstract] [Full Text] [Related]
9. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Connor KM, Aurora SK, Loeys T, Ashina M, Jones C, Giezek H, Massaad R, Williams-Diaz A, Lines C, Ho TW. Headache; 2011 Jan 20; 51(1):73-84. PubMed ID: 21070230 [Abstract] [Full Text] [Related]
17. Randomized, controlled trial of telcagepant over four migraine attacks. Ho AP, Dahlöf CG, Silberstein SD, Saper JR, Ashina M, Kost JT, Froman S, Leibensperger H, Lines CR, Ho TW. Cephalalgia; 2010 Dec 20; 30(12):1443-57. PubMed ID: 20974601 [Abstract] [Full Text] [Related]
18. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine. Tfelt-Hansen P. Headache; 2011 Jan 20; 51(1):118-23. PubMed ID: 21070229 [Abstract] [Full Text] [Related]
19. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Sinclair SR, Kane SA, Van der Schueren BJ, Xiao A, Willson KJ, Boyle J, de Lepeleire I, Xu Y, Hickey L, Denney WS, Li CC, Palcza J, Vanmolkot FH, Depré M, Van Hecken A, Murphy MG, Ho TW, de Hoon JN. Br J Clin Pharmacol; 2010 Jan 20; 69(1):15-22. PubMed ID: 20078608 [Abstract] [Full Text] [Related]